In 2024, the FDA approved a nasal spray as the first at-home influenza vaccination, allowing adults to vaccinate themselves or someone in their care without a needle jab or a trip to the pharmacy.
Intranasal vaccines are in development for RSV, HPV, norovirus, hepatitis B and avian flu. A nasal drop vaccination for Covid-19 is already approved an in use in India, and researchers are evaluating whether a nasal spray might be a more effective method of preventing Covid infections than those drops or the intramuscular injections that are approved in the U.S.
There have also been promising developments with antibodies or peptides delivered via nasal sprays to protect people from infections or to treat them.
To learn more about nasal vaccine devices and how they’re designed, we spoke with Aptar Pharma VP of Scientific Affairs Julie Suman, who’s been working in the nasal space for more than 20 years.
Get the full story at our sister site, Medical Design & Outsourcing.
